OneAscent Financial Services LLC Makes New $544,000 Investment in Abbott Laboratories $ABT

OneAscent Financial Services LLC purchased a new position in Abbott Laboratories (NYSE:ABT) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 5,996 shares of the healthcare product maker’s stock, valued at approximately $544,000.

A number of other hedge funds have also recently made changes to their positions in the stock. BlackRock Inc. raised its holdings in Abbott Laboratories by 4.6% in the second quarter. BlackRock Inc. now owns 152,563,476 shares of the healthcare product maker’s stock worth $13,843,610,000 after purchasing an additional 6,769,518 shares in the last quarter. State Street Corp boosted its holdings in shares of Abbott Laboratories by 2.1% in the 4th quarter. State Street Corp now owns 79,853,782 shares of the healthcare product maker’s stock valued at $10,004,880,000 after buying an additional 1,627,791 shares in the last quarter. Capital International Investors grew its position in shares of Abbott Laboratories by 2.6% in the 4th quarter. Capital International Investors now owns 63,229,445 shares of the healthcare product maker’s stock worth $7,922,519,000 after buying an additional 1,614,706 shares during the last quarter. J. Stern & Co. LLP raised its stake in shares of Abbott Laboratories by 12,439.6% during the 4th quarter. J. Stern & Co. LLP now owns 39,319,009 shares of the healthcare product maker’s stock worth $4,926,279,000 after acquiring an additional 39,005,451 shares in the last quarter. Finally, Capital Research Global Investors raised its stake in shares of Abbott Laboratories by 1.0% during the 4th quarter. Capital Research Global Investors now owns 39,169,239 shares of the healthcare product maker’s stock worth $4,907,523,000 after acquiring an additional 400,400 shares in the last quarter. 75.18% of the stock is currently owned by hedge funds and other institutional investors.

Key Abbott Laboratories News

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: The FDA approved Abbott’s Libre Duo 10 Day Continuous Dual Glucose Ketone Monitoring System for diabetes patients age two and older. The wearable is the first of its kind to track both glucose and ketones, strengthening Abbott’s position in diabetes care and creating potential for future integration with insulin-pump systems. FDA Approves Abbott’s First Wearable Device for Dual Ketone and Glucose Tracking
• Positive Sentiment: Abbott received the European CE Mark for its next-generation Amulet 360 left atrial appendage occluder. The device is designed to reduce stroke risk in certain atrial-fibrillation patients and may reduce reliance on blood-thinning medication, supporting growth in Abbott’s structural-heart business. Abbott’s next-generation Amulet 360 device receives CE Mark
• Positive Sentiment: Analyst coverage remains supportive, with TD Cowen expecting Abbott’s stock to rise. Separately, Zacks highlighted ABT as a strong long-term momentum candidate, suggesting improving price trends and investor interest despite its premium valuation. TD Cowen Analyst Says Abbott Stock Price Expected to Rise
• Neutral Sentiment: Abbott’s latest reported quarter exceeded consensus estimates, with earnings and revenue growing year over year. Management’s 2026 earnings guidance also points to continued expansion, but ABT’s elevated price-to-earnings ratio leaves the stock sensitive to execution and valuation concerns.
• Negative Sentiment: Recent coverage noted that Abbott shares fell 2.2% in the prior session even as the broader market advanced, reflecting near-term underperformance and possible profit-taking. The stock remains well below its 12-month high, so investors may want evidence that the new devices translate into meaningful sales growth. Abbott Stock Sinks as Market Gains

Wall Street Analysts Forecast Growth

Several research firms have issued reports on ABT. Robert W. Baird started coverage on shares of Abbott Laboratories in a report on Wednesday, July 1st. They issued an “outperform” rating and a $121.00 price target on the stock. Royal Bank Of Canada reissued an “outperform” rating and issued a $130.00 price objective on shares of Abbott Laboratories in a research report on Friday, July 17th. Wells Fargo & Company boosted their target price on Abbott Laboratories from $109.00 to $112.00 and gave the stock an “overweight” rating in a research note on Friday, July 17th. Bank of America decreased their price target on Abbott Laboratories from $120.00 to $102.00 in a research note on Friday, June 12th. Finally, JPMorgan Chase & Co. boosted their price target on Abbott Laboratories from $110.00 to $120.00 and gave the stock an “overweight” rating in a research note on Friday, July 17th. Three equities research analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat, Abbott Laboratories currently has a consensus rating of “Moderate Buy” and an average price target of $119.50.

Abbott Laboratories Price Performance

NYSE ABT opened at $112.63 on Monday. The company has a market cap of $194.89 billion, a price-to-earnings ratio of 36.45, a PEG ratio of 2.18 and a beta of 0.59. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.38 and a quick ratio of 0.97. The stock’s fifty day moving average price is $102.61 and its 200 day moving average price is $100.14. Abbott Laboratories has a 1 year low of $81.97 and a 1 year high of $137.49.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 EPS for the quarter, topping analysts’ consensus estimates of $1.28 by $0.03. The company had revenue of $12.59 billion during the quarter, compared to analysts’ expectations of $12.52 billion. Abbott Laboratories had a return on equity of 17.69% and a net margin of 11.65%.The firm’s revenue was up 13.0% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.26 EPS. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. As a group, equities research analysts forecast that Abbott Laboratories will post 5.52 earnings per share for the current year.

Abbott Laboratories Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, August 17th. Investors of record on Wednesday, July 15th were given a $0.63 dividend. The ex-dividend date was Wednesday, July 15th. This represents a $2.52 dividend on an annualized basis and a yield of 2.2%. Abbott Laboratories’s dividend payout ratio is currently 81.55%.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.